Surotomycin

Summary

Surotomycin (CHEMBL2375161) is a phase-3 clinical-stage protein; indicated across 1 condition including clostridium infectious disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 1 condition
• Clinical trials: 5
• Chemistry: 1680.7 Da · C77H101N17O26

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2375161
Name	Surotomycin
Type	Protein
Max phase	3
FDA approved	no
PubChem CID	73345788
Molecular formula	C77H101N17O26
Molecular weight	1680.7
InChIKey	DYNMYYRPPFVAKR-ZXTAUSOFSA-N

SMILES: CCCCCC1=CC=C(C=C1)/C(=C/C(=O)N[C@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H]4[C@H](OC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC4=O)CCCN)CC(=O)O)C)CC(=O)O)CO)[C@H](C)CC(=O)O)CC(=O)C5=CC=CC=C5N)C)/C

IUPAC name: (3S)-3-[[(2R)-4-amino-2-[[(2R)-3-(1H-indol-3-yl)-2-[[(E)-3-(4-pentylphenyl)but-2-enoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-4-[[(3S,6S,9R,15S,18R,21S,24S,30S,31R)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21-bis(carboxymethyl)-6-[(2R)-1-carboxypropan-2-yl]-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-oxa-4,7,10,13,16,19,22,25,28-nonazacyclohentriacont-30-yl]amino]-4-oxobutanoic acid

Also known as: Cb-183, 315, CB-183,315, CB-183315, Surotomicina, Surotomycin, Surotomycine, SUROTOMYCIN

Patent coverage: 43 distinct patent families (96 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Clostridium infectious disease	3	MONDO:0024388	EFO:0009130

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE3	2
PHASE1	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01597505	PHASE3	COMPLETED	Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)
NCT01598311	PHASE3	COMPLETED	A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)
NCT01085591	PHASE2	COMPLETED	Study of CB-183,315 in Participants With Clostridium Difficile Infection
NCT02835105	PHASE1	COMPLETED	A Study of Ascending Single Doses of Surotomycin in Healthy Participants (MK-4261-008)
NCT02835118	PHASE1	COMPLETED	A Study of Ascending Multiple Doses of Oral Surotomycin in Healthy Participants (MK-4261-009)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).